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Abstract
Background. Chronic kidney disease (CKD) is a growing
health problem worldwide that leads to end-stage kidney
failure and cardiovascular complications. We aimed to de-
termine the prevalence of CKD in Turkey, and to evaluate
relationships between CKD and cardiovascular risk factors
in a population-based survey.
Methods. Medical data were collected through home visits
and interviews. Serum creatinine, blood glucose, total
cholesterol, triglycerides, HDL, LDL and uric acid were
determined from 12-h fasting blood samples, and spot
urine tests were performed for subjects who gave consent
to laboratory evaluation.
Results. A total of 10 872 participants were included in
the study. The final analysis was performed on 10 748 sub-
jects (mean age 40.5 ± 16.3 years; 55.7% women) and ex-
cluded 124 pregnant women. A low glomerular filtration
rate (GFR) (<60 mL/min/1.73 m
2) was present in 5.2%
of the subjects who were evaluated for GFR, while micro-
albuminuria and macroalbuminuria were observed in
10.2% and 2% of the subjects, respectively. The presence
of CKD was assessed in subjects who gave consent for
urinary albumin excretion measurement (n =8 7 6 5 ) .T h e
overall prevalence of CKD was 15.7%; it was higher in
women than men (18.4% vs. 12.8%, P < 0.001) and in-
creased with increasing age of the subjects. The prevalence
of hypertension (32.7% in the general population), dia-
betes (12.7%), dyslipidaemia (76.3%), obesity (20.1%)
and metabolic syndrome (31.3%) was significantly higher
in subjects with CKD than subjects without CKD (P <
0.001 for all).
Conclusions. The prevalence of CKD in Turkey is 15.7%.
Cardiovascular risk factors were significantly more preva-
lent in CKD patients.
Keywords: chronic kidney disease; epidemiology and outcomes; risk
factors
Introduction
Chronic kidney disease (CKD) is a growing health prob-
lem worldwide that leads to end-stage kidney failure and
cardiovascular complications [1]. CKD is defined as kid-
ney damage and/or decreased kidney function expressed as
glomerular filtration rate (GFR) for at least 3 months, re-
gardless of the cause [2,3].
CKD is classified into five stages based on the severity
of the disease [2,3]. Annual reports from the United States
Renal Data System (USRDS) and the European Renal
Association–European Dialysis and Transplant Associ-
ation (ERA–EDTA) have shown that incidence and preva-
lence rates of stage 5 CKD, also known as end-stage renal
disease (ESRD), are on the rise [4,5]. International com-
parisons published in the 2009 USRDS atlas indicated that
Taiwan [(415 per million people (pmp)], Jalisco-Mexico
(372 pmp) and the USA (361 pmp) are the countries hav-
ing the highest incidences of ESRD. In terms of preva-
lence, Taiwan (2288 pmp), Japan (2060 pmp) and the
USA (1698 pmp) had the highest rates [5]. The data from
the Turkish Society of Nephrology (TSN) 2008 annual
registry indicated that the incidence of ESRD in Turkey
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lence of ESRD has doubled (incidence, 52 vs. 188 pmp;
prevalence, 358 vs. 756 pmp, respectively) [6,7].
In the USA, the prevalence of stage 1–4C K Dw a s
13.1% according to results from the National Health and
Nutrition Examination Survey (NHANES) 1999–2004
data [8]. In a systematic review of population-based stud-
ies, the median CKD (defined as <60 mL/min/1.73 m
2)
was 7.2% for persons aged 30 years or older but varied
from 23.4% to 35.8% in the elderly population [9].
CKD patients at high risk for developing ESRD need to
be identified and monitored for timely transition to renal
replacement therapy. Moreover, angiotensin-converting en-
zyme (ACE) inhibitors and angiotensin II receptor block-
ers (ARB) appear to have renoprotective effects and may
be used in early-stage CKD to prevent progression of the
disease [10–13].
In this large population-based study, we aimed to deter-
mine the prevalence of CKD in Turkey, and to assess the
relationship between CKD and other cardiovascular risk
factors such as diabetes, hypertension, dyslipidaemia,
obesity and metabolic syndrome.
Materials and methods
Study design
We performed a population-based, national survey in Turkey on popula-
tions aged over 18 years. All subjects included in this survey gave in-
formed consent to participate in the field study. Subjects with cognitive
dysfunction that interfered with understanding and answering the study
questionnaire were excluded from the study.
The study was approved by the Ethics Committee of the Akdeniz Uni-
versity Faculty of Medicine and the Turkish Ministry of Health.
Sampling method
A cluster sampling technique was used to select the study participants. A
sampling frame was defined as the seven official geographical regions of
Turkey, which included 81 cities. The study sample comprised 23 cities
such that a minimum 50% of the total population in each geographical
region formed a sampling outline by including both the city with the high-
est population and a randomly selected city with a low population in each
geographical area.
The list of districts involved in the postal area codes of the selected
cities was used to determine the cluster sampling outline for urban areas.
The list of residences within 80 km of the centre of the selected cities,
which are defined as rural areas according to the Turkish Statistical Insti-
tute [14] classification, was used to determine the cluster sampling outline
for rural areas.
The sample size of the study included ~10 500 participants, and the
prevalence of CKD was estimated with a 95% confidence interval accord-
ing to the National Kidney Foundation Kidney Disease Outcomes Quality
Initiatives (NKF KDOQI) practice guidelines and the NHANES-III
[2,15]. The number of subjects in each study subgroup was calculated
on the basis of age distribution of women and men in each geographical
area (since the sampling method was cluster sampling, the effect size was
set at 1.2).
Field study
The data were collected through home visit and interviews of potential
participants by specially trained field study teams. During interviews,
the study questionnaire was given which included questions on subject
demographics, socioeconomic status, diet, lifestyle, current diseases and
drugs, family history, and other relevant medical history. In addition,
height, weight, waist circumference and blood pressure were measured.
Blood pressure was measured two times at 2-min intervals from both
arms, and the average of the two measurements was recorded.
Laboratory assessment
Laboratory assessment was performed for subjects who gave written con-
sent for the laboratory evaluation during interviews. These subjects were
visited the next day to collect 12-h fasting blood samples. At the same
time, morning spot urine samples were obtained from the participants.
Additionally, spot urine analysis (by dipsticks) was performed during
home visits, and results were recorded on the study questionnaire. Albu-
minuria measurements were excluded in pregnant or menstruating women
and in all patients suffering from febrile illness [16].
Urine albumin (immunoturbidimetric method) and creatinine (alkaline
picrate method), serum creatinine (alkaline picrate method), blood glu-
cose (hexokinase method), total cholesterol (cholesterol oxidase method),
triglycerides (glycerol phosphate oxidase method), HDL cholesterol (ac-
celerator selective detergent method), LDL cholesterol, and uric acid (uri-
case method) concentrations were determined.
Definitions
Serum creatinine levels, estimated GFR and spot urine microalbuminuria
were studied as markers for kidney function.
CKD was defined as kidney damage with or without a decrease in
GFR, which was calculated using a simplified version of the Modifica-
tion of Diet in Renal Disease (MDRD) formula [186 × (Scr)
−1.154 ×
(Age)
−0.203 × (0.742 if woman) × (1.212 if African American)] [17].
Since there were no African American subjects in our study population,
the last variable of the formula was not used.
CKD was categorized into five stages based on the classification sys-
tem established by the NKF KDOQI [2]: stage 1, signs of kidney damage
as evidenced by microalbuminuria or macroalbuminuria and normal GFR
(≥90 mL/min/1.73 m
2); stage 2, microalbuminuria or macroalbuminuria
and with mild decrease in GFR (60–89 mL/min/1.73 m
2); stage 3, mod-
erate decrease in GFR (30–59 mL/min/1.73 m
2); stage 4, severe decrease
in GFR (15–29 mL/min/1.73 m
2); and stage 5, GFR <15 mL/min/1.73 m
2
or dialysis.
The urinary albumin-to-creatinine ratio was determined as milligrams
per gram. Albuminuria is defined as an albumin-to-creatinine ratio of
30 mg/g or higher, with microalbuminuria defined as an albumin-to-
creatinine ratio of 30–299 mg/g, and macroalbuminuria defined as an
albumin-to-creatinine ratio of 300 mg/g or higher [18].
For the purpose of this study, ‘hypertension’ was assumed to be
present if there was a recorded diagnosis of hypertension, systolic blood
pressure >140 mmHg and/or diastolic blood pressure ≥90 mmHg.
‘Diabetes mellitus’ was defined as diagnosis of diabetes mellitus or fast-
ing blood glucose ≥126 mg/dL. The term ‘dyslipidaemia’ indicated pa-
tients having anti-lipid treatment or dyslipidaemia shown in the lipid
profile (total cholesterol >240 mg/dL or LDL cholesterol >130 mg/dL
or HDL cholesterol <40 mg/dL for men, <46 mg/dL for women, or serum
triglyceride >150 mg/dL). The term ‘obesity’ indicated a body mass index
≥30 kg/m
2. The American Heart Association (AHA) criteria were used
for the diagnosis of metabolic syndrome, which included the presence
of three or more of the following components: elevated waist circumfer-
ence (for men ≥102 cm and for women ≥88 cm), elevated triglycerides
(≥150 mg/dL), reduced HDL (for men <40 mg/dL and for women
<50 mg/dL), elevated blood pressure (≥130/85 mmHg) or elevated fast-
ing glucose (≥100 mg/dL) [19].
Statistical analysis
Analyses were performed on populations weighted according to age
groups, gender, geographical area and residence. Student's t-tests and
Mann–Whitney U-tests were used for comparisons of continuous vari-
ables, which showed normal and non-normal distribution, respectively.
Chi-square tests were used to compare proportions between groups.
The Mantel–Haenszel test for linear association was used to test the sig-
nificance of linear relationships between ordinal variables. The relative
risk of risk factors for CKD prevalence was expressed as odds ratios
with 95% confidence intervals (CI). Statistical significance was defined
as P <0.05.
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Study population
A total of 10 872 participants from throughout the country
were included in the study. The data from 124 pregnant
women were excluded, giving a final total of 10 748 sub-
jects. The majority of the study population (71.6%) came
from urban areas, while the remainder lived in rural areas.
The distribution of subjects according to the geographical
regions of Turkey was parallel to the population density of
the regions, which is highest in the Marmara, Central Ana-
tolia and the Aegean Regions. The mean age of subjects
was 40.5 ± 16.3 years. The distribution of subject age
groups showed that the majority of subjects (>70%) were
aged below 50 years. Of all the subjects, 55.7% were
women (Table 1).
Kidney function
Creatinine levels and GFR were determined in 10 056 sub-
jects, and microalbuminuria as well as urinalysis was per-
formed in 9064 subjects.
Serum creatinine. Overall, the mean creatinine level of the
subjects was 0.90 ± 0.28 mg/dL. The creatinine level was
significantly higher in men than women (1.00 ± 0.29 mg/
dL and 0.80 ± 0.23 mg/dL, respectively, P < 0.001). There
was a slight increase in creatinine level with increasing age
(Table 2).
Glomerular filtration rate. The estimated mean GFR was
91.8±20.9mL/min/1.73m
2,anditwassignificantlyhigher
in men and in younger groups of subjects (P < 0.001, for
both analyses) (Table 2).
Decreased kidney function, defined as a moderate or se-
vere decrease in GFR, was detected in 4.4% of the subjects
who were evaluated for GFR. A moderate decrease (GFR,
30–59 mL/min/1.73 m
2) was observed in 4.1%, while a
GFR of 15–29 mL/min/1.73 m
2 was noted in 0.24%,
and a GFR <15 mL/min/1.73 m
2 GFR in 0.13%. Increas-
ing subject age produced a consistent increase in the preva-
lence of mild and moderate decreases in GFR (P < 0.001)
(Figure 1).
Microalbuminuria. Of all the subjects, 10.2% had mi-
croalbuminuria, and 2% had macroalbuminuria. Both of
these, particularly microalbuminuria, were higher in fe-
males and in older age groups (Figure 2). Spot urine tests
revealed that the median (IQR) albuminuria level was 6.59
(10.05) mg/g creatinine. The median albuminuria was sig-
nificantly higher for women than men (7.55 vs. 5.71 mg/g
creatinine, respectively, P < 0.001). It was also significantly
higher for patients aged over 50 years (Table 2).
Prevalence of CKD
The presence of CKD was assessed in all subjects who vo-
lunteered for urinary albumin excretion measurements.
The prevalence of CKD was 15.7% (n = 1373) among
8765 subjects evaluated. CKD was significantly more
common among women than men [18.4% vs. 12.8%,
P < 0.001, odds ratio 1.54 (95% CI: 1.37–1.74)] (Table 3).
The prevalence of CKD also increased with increasing age
of the subjects. The odds ratios of CKD ranged from 1.45
(95% CI: 1.14–1.84) to 2.18 (95% CI: 1.76–2.70) for every
10-year increase in age for subjects over 30 years (Table 3).
The prevalence of CKD was found to be 11.5% in the popu-
lation aged <60 years, while it was as high as 38.3% in sub-
jects aged 60 years or over [P < 0.001, odds ratio 1.43 (95%
CI: 1.37–1.49)]. Stage 3 CKD was especially more com-
mon among subjects aged over 60 years (1.6% vs.
21.5%). CKD prevalence was slightly higher among sub-
jects living in rural areas than in those living in urban areas
(16.8% vs. 15.2%, P= 0.049). CKD prevalencewas highest
among subjects from the Marmara region (19.7%) followed
by Southeastern Anatolia (18.6%), the Black Sea (16.1%),
East Anatolia (14.2%), the Aegean (13.8%), Central Ana-
tolia (12.6%) and the Mediterranean (11.7%) regions.
The majority of subjects with CKD were in stage 1–3.
The prevalence rates for CKD stage 1, 2, 3, 4 and 5 were
5.4%, 5.2%, 4.7%, 0.3% and 0.2%, respectively. The per-
centage of subjects in stage 2 and 3 increased and those
with stage 1 decreased with increasing age (Figure 3).
Concomitant cardiovascular risk factors
In thegeneral population, the prevalence rates for hyperten-
sion, diabetes, dyslipidaemia, obesity and metabolic syn-
drome were 32.7%, 12.7%, 76.3%, 20.1% and 31.3%,
respectively. The prevalence of hypertension was higher
in subjects with CKD than in those without CKD (56.3%
and 31%, P < 0.001). Similarly, the prevalence rates of dia-
betes (26.6% vs. 10.1%), dyslipidaemia (83.4% vs.
75.8%), obesity (29.2% vs. 20%) and metabolic syndrome
(46% vs. 29.8%) were significantly higher in subjects with
Table 1. Characteristics of the study population (n = 10 748)
n (%) or mean ± SD
Gender Female 5983 (55.7%)
Male 4765 (44.3%)
Mean age (years) Total 40.54 ± 16.30
Female 41.16 ± 16.71
Male 39.91 ± 15.86
Age groups <30 years 1902 (17.7%)
30–39 years 2540 (23.6%)
40–49 years 2196 (20.4%)
50–59 years 1816 (16.9%)
60–69 years 1594 (14.8%)
70–79 years 573 (5.3%)
≥80 years 127 (1.2%)
Residence Urban 7697 (71.6%)
Rural 3051 (28.4%)
Geographical region Central Anatolia 2073 (19.3%)
Mediterranean 975 (9.1%)
Marmara 4502 (41.9%)
Aegean 910 (8.5%)
East Anatolia 646 (6%)
Southeastern Anatolia 676 (6.3%)
Black Sea 966 (9%)
The number of subjects is crude (unadjusted) figures.
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all analyses). Furthermore, the prevalence of these cardio-
vascular risk factors gradually increased in subjects having
advanced stages of the disease. Thus, CKD was found to
be strongly associated with these cardiovascular risk fac-
tors (Table 4).
Mean values of kidney function and/or damage indica-
tors, such as serum creatinine, GFR and microalbuminuria,
in subjects with and without hypertension, diabetes, dysli-
pidaemia, obesity and metabolic syndrome also demon-
strated that renal function in subjects with cardiovascular
risk factors was significantly impaired compared with
healthy individuals (Table 5). The prevalence of decreased
GFR and microalbuminuria was higher in subjects having
these risk factors, particularly in those having hypertension
and diabetes (Figure 4). The prevalence of CKD among
subjects with and without hypertension was 25.3% and
10.6%, respectively [P < 0.001, odds ratio 1.58 (95% CI:
1.48–1.68)]. Similarly, CKD was significantly more com-
mon in subjects with diabetes than in subjects without dia-
Table 2. Mean serum creatinine, glomerular filtration rate and microalbuminuria with respect to gender and age groups of the study population
Serum creatinine (mg/dL) GFR (mL/min/1.73 m
2) Albuminuria (mg/g creatinine)
n Mean ± SD P-value n Mean ± SD P-value n Mean ± SD (median; IQR) P-value
Gender
Female 5110 0.80 ± 0.23 <0.001 5110 89.6 ± 19.9 <0.001 4615 35.1 ± 165.6 (7.55; 10.95) <0.001
Male 4947 1.00 ± 0.29 4947 94.2 ± 21.6 4449 28.9 ± 145.2 (5.71; 8.75)
Age groups
a
<30 3137 0.86 ± 0.19 3137 105.6 ± 20.4 2696 24.4 ± 91.5 (6.18; 8.36)
30–39 2241 0.88 ± 0.25 0.064 2241 94.4 ± 16.8 <0.001 2030 21.4 ± 100.4 (5.76; 7.63) 0.021
40–49 1860 0.90 ± 0.22 0.43 1860 87.8 ± 15.4 <0.001 1700 33.3 ± 228.6 (5.90; 8.75) 0.68
50–59 1333 0.95 ± 0.48 <0.001 1333 81 ± 15.8 <0.001 1259 43.9 ± 189 (7.27; 13.21) <0.001
60–69 790 0.95 ± 0.33 0.99 790 77 ± 16 <0.001 728 53.5 ± 201.3 (8.76; 18.95) 0.051
70–79 543 0.99 ± 0.27 0.12 543 71 ± 17.4 <0.001 502 46 ± 153.3 (11.65; 21.34) 0.001
≥80 153 0.99 ± 0.22 0.99 153 67.6 ± 14.6 0.32 150 50.3 ± 99.2 (14.93; 29.96) 0.006
Total 10 056 0.90 ± 0.28 10 056 91.8 ± 20.9 9064 32.1 ± 156 (6.59; 10.05)
The numbers of subjects are adjusted (to age, gender, geographic region and residence) figures.
GFR, glomerular filtration rate; SD, standard deviation; IQR, interquartile range.
aP-values correspond to the comparisons with previous age group.
Fig. 1. Percentage of subjects according to glomerular filtration rate with respect to gender and age groups. There was a significant relation between the
stage of glomerular filtration rate and age group (P < 0.001).
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1.18–1.27)].
Discussion
This was the first epidemiological study to assess the preva-
lence of CKD in Turkey. Using the criteria of CKD estab-
lished by the KDOQI guidelines, the overall prevalence of
CKD in Turkey was 15.7%. By employing similar KDOQI
criteria, the prevalence of CKD was 13.1% in the USA
based on the NHANES-III (1999–2004) data [8] and
10.2% in Norway based on the HUNT-II (1995–97) data
[20]. Although the US and Norwegian studies showed the
highest prevalence for stage 3 CKD (7.7% in the USA and
4.2% in Norway), our Turkish stage 1–3 cohort were more
evenly distributed, and each comprised nearly one-third of
the CKD population. This suggests that Turkey shows a
higher proportion of albuminuria in the absence of kidney
dysfunction.
A number of studies have focused on the prevalence of
stage 3–5 CKD based on GFR <60 mL/min/1.73 m
2 and
calculated GFRs using the MDRD equation. The preva-
lence of lowestimated GFR in Turkey (5.2%) is lower com-
pared with Italy (6.4%) [21], Switzerland (8.1%) [22] and
Iceland (7.2%) [23], but is higher than India (4.2%) [24]
and China (2.5%) [25].
The MDRD equation has mostly been replaced with the
Cockcroft–Gault equation since the latter gives a more ac-
curate estimate of GFR in CKD patients [17]. In epidemio-
logical studies that reported CKD rates using both
equations, the Cockcroft–Gault-calculated rate was always
higher than the MDRD-calculated rate. As an example, the
NHANES-III 1988–94 survey showed that the US preva-
lence of low GFR was 4.5% by the MDRD and 7% by the
Cockcroft–Gault equation [15].
An earlier diagnosis of stage 4 CKD patients would
allow for future planning, such as early access (peritoneal
dialysis catheter or arteriovenous fistula) for dialysis or
transplantation from a donor in the family [26,27]. Fur-
thermore, knowledge on the prospective incidence of
ESRD from a well-established population-based cohort
will help in identifying those patients at the highest risk
for developing this condition.
Fig. 2. Percentage of subjects with microalbuminuria (30–299 mg/g creatinine) or macroalbuminuria (>300 mg/g creatinine) with respect to gender and
age group.
Table 3. The prevalence of chronic renal disease with respect to gender
and age groups
Total number
of subjects
Subjects
with CKD,
n (%) P-value
Odds ratio
(95% CI)
Gender
Female 4490 827 (18.4%) <0.001 1.54 (1.37–1.74)
Male 4273 546 (12.8%)
Age groups
a
<30 2595 259 (10%)
30–39 1947 165 (8.5%) 0.084 0.84 (0.68–1.02)
40–49 1645 207 (12.6%) <0.001 1.56 (1.25–1.93)
50–59 1218 222 (18.2%) <0.001 1.55 (1.26–1.90)
60–69 719 235 (32.7%) <0.001 2.18 (1.76–2.70)
70–79 491 203 (41.3%) 0.002 1.45 (1.14–1.84)
≥80 150 82 (54.7%) 0.004 1.71 (1.18–2.47)
Total 8765 1373 (15.7%)
The numbers of subjects are adjusted (to age, gender, geographic region
and residence) figures.
CKD, chronic renal disease; CI, confidence interval.
aP-values correspond to the comparisons with previous age group.
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spective studies such as the Okinawa screen, the Multiple
Risk Factor Intervention Trial (MRFIT) and the Norwegian
HUNT study. In a 10-year follow-up of the Okinawa popu-
lation, proteinuria, haematuria and hypertension were iden-
tified as predictors of ESRD [28]. In contrast, proteinuria
and estimated GFR were ESRD predictors in the MRFIT
study having a 25-year follow-up [29]. However, their pre-
dictive value was limited since the combined GFR and pro-
teinuria could detect only 27% of the eventual ESRD cases
[29,30]. A 10-year follow-up of HUNT-II showed that the
combination of the albumin/creatinine ratio (not just pro-
teinuria) and estimated GFR narrowed the population at
risk for developing ESRD to 1.4% and correctly predicted
66% of the patients eventually progressing to ESRD [31].
The Kidney Early Evaluation Program (KEEP) study
conducted by the National Kidney Foundation revealed
an independent relationship between CVD and several
measures of CKD, such as estimated GFR, microalbumi-
nuria and anaemia [32]. The early detection and manage-
ment of cardiovascular risk factors will be important for
Turkey since the mortality pattern is very similar to that
of developed nations even though industrialization is on-
going, the population is young, and overall cholesterol le-
vels are comparatively low [33]. Turkey was one of the 22
European countries participating in the EUROASPIRE III
Fig. 3. Percentage of subjects with chronic renal disease according to the stages of the disease with respect to gender and age group.
Table 4. The frequency of concomitant hypertension, diabetes mellitus, dyslipidaemia, obesity or metabolic syndrome in the study population with
respect to presence and stage of chronic renal disease
Chronic renal
disease status
Hypertension Diabetes mellitus Dyslipidaemia Obesity Metabolic syndrome
% OR (95% CI) % OR (95% CI) % OR (95% CI) % OR (95% CI) % OR (95% CI)
General population 32.7 12.7 76.3 20.1 31.3
No CKD 31 reference 10.1 reference 75.8 reference 20 reference 29.8 reference
CKD (any stage)
a 56.3 2.86 (2.54–3.22) 26.6 3.22 (2.77–3.74) 83.4 1.60 (1.37–1.86) 29.2 1.65 (1.45–1.88) 46 2.01 (1.77–2.27)
Stage 1 CKD
b 34.8 1.19 (0.98–1.45) 16.4 1.73 (1.33–2.26) 74.3 0.92 (0.74–1.14) 23.7 1.25 (1–1.55) 31.1 1.06 (0.86–1.31)
Stage 2 CKD
c 55.1 2.30 (1.76–3) 32.1 2.41 (1.74–3.35) 84.2 1.85 (1.33–2.57) 29.7 1.36 (1.01–1.82) 51.4 2.34 (1.77–3.11)
Stage 3 CKD
c 79.8 3.21 (2.36–4.36) 32.3 1.01 (0.74–1.38) 92.6 2.36 (1.50–3.70) 34.7 1.26 (0.95–1.68) 57 1.26 (0.94–1.68)
Stage 4 CKD
c 82.6 1.21 (0.40–3.64) 40.9 1.45 (0.60–3.49) 87.5 0.56 (0.16–1.97) 29.2 0.82 (0.33–2.04) 68.2 1.62 (0.64–4.06)
Stage 5 CKD
c 92.3 2.53 (0.25–25.38) 45.5 1.20 (0.28–5.18) 91.7 1 57 (0.15–16.94) 33.3 1.14 (0.26–5.09) 66.7 0.93 (0.21–4.18)
Significant ORs are denoted in italic font type.
Hypertension (HT), diagnosis of HTor blood pressure ≥140/90 mmHg; diabetes mellitus (DM), diagnosis of DM or fasting blood glucose ≥126 mg/dL;
dyslipidaemia,anti-lipiduseordyslipidaemiainlipidprofile;obesity,bodymassindex≥30kg/m
2;metabolicsyndrome,asdefinedaccordingtotheAHA
criteria; OR, odds ratio.
aCKD of any stage vs. no CKD.
bStage 1 vs. no CKD.
cVersus previous stage.
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therapeutic management of coronary heart disease pa-
tients. In this study, 20% of the Turkish patients hospita-
lized for coronary heart disease were under 50 years of
age, constituting the youngest patients in all of Europe
[34,35]. Moreover, the prospective Turkish Adult Risk
Factors study, a large population-based survey that accu-
mulated data on coronary heart disease and related risk
factors since 1990, has shown that coronary mortality is
highest in Turkey among 30 European countries at 7.6
per 1000 person-years for men and 3.84 for women in
the age group of 45–74 years [36].
In the present cohort, we found that the overall preva-
lence of diabetes was 12.7%. In contrast, the TURDEP
study in 2002 had predicted a prevalence of 7.2% in the
overall Turkish population [37]. This increased prevalence
may be related to increased life expectancy as well as life-
style changes in the Turkish population, such as changes in
dietary habits, more sedentary lifestyle and increased
urbanization. In a more recent study in an older population
cohort, the prevalence of diabetes was 11% of individuals
aged over 35 years [38]. The prevalence of diabetes was
more than doubled in subjects diagnosed with CKD
(26.6%). Diabetes was clearly associated with CKD pro-
gression since the prevalence of diabetic patients increased
with advanced stages of kidney disease. Kidney damage is
very common in diabetes. For example, the NHANES-III
showed that close to one-third of the diabetic population
(28.8%) in the USA had microalbuminuria [39].
Hypertension is the second major cause of ESRD, and is
also very common in Turkey. The prevalence, awareness,
treatment and control of hypertension in Turkey (PatenT)
study reported that the age- and sex-adjusted rate of hyper-
tension was 31.8% in a population of ~15 million people
[40]. A 4-year follow-up of this study showed that the in-
cidence rate of hypertension in Turkey was 21.4%, and this
reached as high as 43.4% for individuals aged over 65 years
[41]. Our current study showed that the percentage of pa-
tientswithhypertension increased steadily with progressing
CKD, such that nearly all patients with ESRD (92.3%) had
elevated blood pressure.
Obesity and metabolic syndrome are also risk factors for
CKD. In a Swedish study, obesity (in men) and morbid
obesity (in women) at anytime during the lifespan were as-
sociated with a 3–4-fold increase in the risk of CKD [42].
In a prospective 9-year study, the odds ratio of incident
CKD was 1.24 among subjects with metabolic syndrome
after adjustments for diabetes and hypertension [43]. Obes-
ity and metabolic syndrome were highly prevalent in this
cohort, and the prevalence of both risk factors was signifi-
cantly greater in subjects with CKD. Even higher rates of
obesity (one-third of the adult population) have been re-
ported in some Turkish studies, while metabolic syndrome
ranged from 18% to 41% depending on the definition
[44,45].
The major limitation of this study was the use of single
measurements to detect serum creatinine and albuminuria.
Many of those screened may have had transient albumin-
uria or a transient decline in GFR. Ideally, a repeat test
should be performed after a few months to eliminate cases
with transient kidney injury, which is relevant at the indi-
vidual level. Nevertheless, it is difficult to perform more
than single testing in large-scale cross-sectional surveys
at the population level [24,46]. Another limitation was
the difficulty of diagnosing elderly subjects having re-
duced GFR with CKD. The prevalence of CKD, particular-
ly stage 3 CKD, was found to be significantly higher in
subjects aged 60 years and older. However, it is very likely
that most of the elderly participants had age-related renal
impairments rather than CKD [47], making it necessary to
evaluate age-related renal functional changes during evalu-
ation of high-prevalence CKD among subjects aged over
60 years. In addition, the MDRD equation has not been
validated for the Turkish population, and its accuracy in
predicting actual GFR in Turkish men and women is not
known. A validation study for the MDRD equation in
the Turkish population is currently being conducted by
the Turkish Society of Nephrology.
In conclusion, similar to many other countries, CKD is a
majorhealthprobleminTurkey.AssociationsbetweenCKD
andseveralcardiovascular riskfactorsemphasizethat thisis
amajor publichealthproblemandamajor predictorofover-
Table 5. Mean serum creatinine, glomerular filtration rate and microalbuminuria in subjects with and without concomitant hypertension, diabetes
mellitus, dyslipidaemia, obesity or metabolic syndrome
Serum creatinine (mg/dL) GFR (mL/min/1.73 m
2) Microalbuminuria (mg/g creatinine)
Mean ± SD P-value Mean ± SD P-value Mean ± SD (median; IQR) P-value
Hypertension No 0.88 ± 0.18 <0.001 96.5 ± 20.3 <0.001 25.9 ± 146.7 (5.98; 8.15) <0.001
Yes 0.94 ± 0.42 82.6 ± 19.2 45 ± 176.6 (8.10; 14.77)
Diabetes mellitus No 0.88 ± 0.26 <0.001 94 ± 20.8 <0.001 27.1 ± 144.5 (6.23; 8.83) <0.001
Yes 0.94 ± 0.44 82 ± 19.4 74.1 ± 260.5 (10.76; 25.22)
Dyslipidaemia No 0.85 ± 0.20 <0.001 100.5 ± 21.8 <0.001 32.1 ± 211.5 (6.31; 8.74) 0.006
Yes 0.91 ± 0.30 89.2 ± 19.9 31.8 ± 137.3 (6.65; 10.45)
Obesity No 0.90 ± 0.28 0.17 93.7 ± 21.1 <0.001 29.7 ± 143.7 (6.42; 9.33) <0.001
Yes 0.90 ± 0.30 84.7 ± 18.5 41.3 ± 196.2 (7.42; 12.35)
Metabolic syndrome No 0.88 ± 0.25 <0.001 95.9 ± 21 <0.001 27.9 ± 156 (6.18; 8.73) <0.001
Yes 0.92 ± 0.35 83.9 ± 18.4 42.7 ± 178.5 (7.57; 13.42)
Hypertension (HT), diagnosis of HT or blood pressure ≥140/90 mmHg; diabetes mellitus (DM), diagnosis of DM or fasting blood glucose ≥126 mg/
dL; dyslipidaemia, anti-lipid use or dyslipidaemia in lipid profile; obesity, body mass index ≥30 kg/m
2; metabolic syndrome, as defined according to
the AHA criteria; GFR, glomerular filtration rate; SD, standard deviation; IQR, interquartile range.
1868 G. Süleymanlar et al.all morbidity and mortality. Longitudinal studies will be
needed to establish relationships between GFR, microalbu-
minuria,cardiovascularoutcomesandtheriskforESRDde-
velopment. The population examined in the present study is
currently being followed up as a longitudinal study, and re-
sults will be evaluated at the fifth year.
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Abstract
Background. Hypertensive nephrosclerosis alone and in
combination with other renal diseases is a leading cause
of terminal renal insufficiency. Histologic lesions manifest
as benign nephrosclerosis (bN) with arteriolar hyalinosis
and later fibrosis. Procoagulant micromilieus have been
implicated in fibrosis. Hyalinosis is considered to consist
of plasma insudation possibly containing procoagulant fac-
tors like von Willebrand factor (VWF). Therefore, it is hy-
pothesized that VWF cleaving protease ADAMTS13 (a
disintegrin-like and metalloprotease with thrombospondin
type-1 motif, 13) is normally expressed by arteriolar vas-
cular smooth muscle cells (VSMCs) and diminished in bN
and that this reduction contributes to fibrosis in bN.
Methods. ADAMTS13 expression was examined by im-
munohistochemistry and quantitative real-time polymerase
chain reaction in VSMCs of various human organs. Fifty-
four specimens with and seven without bN were immunos-
tained for ADAMTS13, VWF, CD61 and VSMC differen-
tiation markers in arteriolar walls.
Results. Expression of ADAMTS13 is confirmed in
VSMCs. In bN, ADAMTS13 immunostaining of arterial
VSMCs correlated inversely with fibrotic but not hyalino-
tic lesions. Smooth muscle myosin heavy chain showed an
inverse correlation with hyalinotic, as opposed to fibrotic
lesions of bN. Smoothelin showed an inverse correlation
with both hyalinotic and fibrotic lesions of bN. VWF
was absent in normal controls and hyalinotic lesions, but
present exclusively in fibrotic lesions in 7/54 (13%) bN
cases. CD61 was absent in all arteriolar walls.
Conclusions. The present results establish ADAMTS13 as
a novel marker of contractile VSMCs that is retained in
early hyalinotic bN but partially lost later in fibrotic bN.
Loss of ADAMTS13 and accumulation of VWF in fibrotic
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